Risk-reducing mastectomy

What the operation is

A risk-reducing mastectomy, sometimes called a prophylactic mastectomy, is the surgical removal of healthy breast tissue to reduce the future risk of developing breast cancer in patients who carry a substantially raised lifetime risk. Almost all are bilateral (both breasts), with immediate reconstruction, and are typically performed using skin-sparing or nipple-sparing technique to preserve as much of the natural appearance as possible.

This is one of the few areas in surgery where a major operation is offered to a patient who, at the time of surgery, is not unwell. That asymmetry, operating on healthy tissue, is taken seriously. A risk-reducing mastectomy is never a routine recommendation; it is a discussion that needs unhurried time, full information, and clear understanding of the alternatives.

Who it is offered to

Risk-reducing mastectomy is considered for patients whose lifetime risk of breast cancer is sufficiently high that the operation offers a meaningful reduction over surveillance alone. The most common groups are:

• BRCA1 carriers: cumulative breast cancer risk to age 80 of around 70–80% (estimates vary by study and family).
• BRCA2 carriers: cumulative risk to age 80 of around 65–80%.
• PALB2 carriers: lifetime risk approximately 35–55%, varying with family history (Yang et al., 2020).
• TP53 (Li-Fraumeni) carriers: substantially raised risk, often presenting at younger ages.
• Other moderate-penetrance gene carriers, for example CHEK2 or ATM, where the gene mutation combines with a strong family history to push the formally assessed lifetime risk into the high-risk category (≥30%). Risk-reducing mastectomy is not routinely offered for a moderate-risk gene alone.
• Patients with a very strong family history (typically multiple first- and second-degree relatives with early breast and/or ovarian cancer) but no identified gene, where formal risk assessment puts the lifetime risk at over ~30%.

When the other breast is removed after a cancer diagnosis

What the operation is

A contralateral risk-reducing mastectomy, sometimes shortened to CRRM, is the surgical removal of the healthy, unaffected breast in a patient who has been treated, or is being treated, for a cancer in the other breast. The aim is to reduce the risk of a future primary cancer developing in that second breast.

It is a different conversation from risk-reducing mastectomy when there is no prior cancer, even though the operation itself is the same. The decision depends on your first cancer, your genetic and family-history picture, the treatment plan for that cancer, and what matters most to you after a recent diagnosis.

This page is for patients who are considering a contralateral mastectomy at the same time as their cancer surgery (a bilateral mastectomy, with one side cancer surgery and the other side risk-reducing), or as a separate operation later in the cancer pathway.

When it is considered

Contralateral risk-reducing mastectomy is most clearly justified, and most often recommended, when the patient carries a substantially raised risk of a future cancer in the other breast:

• Confirmed BRCA1, BRCA2, or PALB2 mutation: the lifetime risk of a second primary cancer in the other breast is substantially raised, and surgical risk reduction in the unaffected breast is supported by good evidence.
• TP53 (Li-Fraumeni) mutation or another strongly inherited cancer gene.
• Very strong family history of breast or ovarian cancer that meets the threshold for high-risk classification, even without an identified gene.

How much CRRM reduces the chance of a new cancer in the other breast depends on the underlying risk. For BRCA1 and BRCA2 carriers, surgery removes about 90–95% of the at-risk tissue and is expected to give a similar reduction in future breast cancer risk (NCI 2024; ABS 2017). The evidence in PALB2, TP53 (Li-Fraumeni) and strong family history without a confirmed gene is less mature; the same magnitude of reduction is expected biologically, but the published evidence is smaller and the size of benefit is less certain (NHS Genomics Education Programme, PALB2 Knowledge Hub, 2024).

When it is a more open conversation

Outside of the high-risk genetic groups, the conversation is more nuanced. Many patients with a primary breast cancer ask about removing the other breast. In plain terms:

• Average-risk patients with a unilateral, treated primary cancer have a future risk of cancer in the other breast that is similar to or slightly higher than the population risk, typically in the order of 0.5–1% per year, depending on the first cancer and on hormonal treatment.
• Modern breast surveillance (annual mammography, sometimes with MRI) catches most contralateral cancers at an early, treatable stage.
• Endocrine treatment (such as tamoxifen or an aromatase inhibitor like anastrozole) for the original cancer reduces the chance of a new cancer in the other breast by roughly 40–50%. The protection continues for at least 5–10 years after the medication is stopped (EBCTCG, Lancet 2011).

For patients without a high-risk genetic factor, the evidence does not show that removing the healthy breast helps you live longer. Most studies, including a Cochrane review (2018) and the ABS UK position statement (2017), find no overall survival benefit from contralateral risk-reducing mastectomy in this group. This is because the outlook from the original cancer is mainly set by its own biology and treatment, and most second cancers in the other breast are picked up early enough by surveillance to be treated successfully. CRRM still has a role for some patients in this group (for symmetry after a unilateral mastectomy, for reduced anxiety, or for simpler follow-up) but not as a way to improve survival. This does not mean the operation has no role in this group. For some patients the psychological benefit (reduced anxiety about the other breast, simpler imaging follow-up, symmetry after a unilateral mastectomy) is itself a meaningful reason. But it is a different conversation from the high-risk genetic situation.

The honest framing is something like: for high-risk gene carriers, CRRM is recommended on risk grounds; for others, it is an option that some patients choose for reasons that go beyond strict survival benefit, and choosing not to have it is also entirely reasonable.

Reasons patients choose CRRM

Reasons commonly cited by patients who choose contralateral mastectomy include one or more of:

• A confirmed high-risk genetic mutation identified during the cancer pathway.
• A strong family history that, although not meeting strict gene-mutation criteria, raises concern.
• Symmetry after a unilateral mastectomy: particularly when reconstruction is part of the plan, bilateral mastectomy with bilateral reconstruction often gives a more symmetric long-term result than a unilateral mastectomy alone.
• Anxiety about the other breast: for some patients, the worry of a future second cancer is a meaningful daily burden, and surgical risk reduction relieves it in a way that surveillance does not.
• Avoiding future imaging burden: annual mammography and MRI for many years is a real commitment; some patients find it preferable to remove the unaffected breast and step out of that surveillance pathway.
• A previous history of difficult biopsies or recall: patients who have had repeated work-up of the contralateral breast for benign findings sometimes prefer mastectomy to ongoing investigation.

None of these is, on its own, a “right” reason. They are real considerations that patients weigh in the context of a cancer diagnosis, and a good consultation surfaces them rather than dismissing them.

Reasons patients choose not to have CRRM

Equally legitimate reasons to decline contralateral mastectomy:

• No identified high-risk gene: for many patients, the survival case is not strong, and the risks of additional surgery are real.
• Wish to preserve normal breast tissue and sensation on the unaffected side.
• Concerns about a longer recovery: bilateral surgery is more demanding than unilateral, particularly when combined with reconstruction.
• Not wanting to make further surgical decisions during treatment: the cancer pathway itself is a lot to navigate; some patients prefer to focus on the first cancer treatment and revisit the contralateral question later, if at all.
• Concerns about implant or reconstruction issues on a healthy breast: for patients having implant-based reconstruction on the cancer side, accepting the same on the healthy side means accepting the same long-term implant considerations bilaterally.

The decision can also be deferred. Many patients have unilateral surgery for the cancer and revisit contralateral mastectomy as a separate decision months or years later. The option does not disappear after the primary surgery.

Timing: at the same time, or later?

Two paths:

Same-operation bilateral mastectomy

CRRM is performed at the same operation as the cancer mastectomy, with bilateral reconstruction (where chosen). This has practical advantages:

• A single recovery rather than two.
• Symmetric reconstruction from day one: easier to match two newly reconstructed breasts than to match a reconstructed breast to an unoperated breast later.
• A single anaesthetic.

Disadvantages: a longer single operation, more demanding recovery in the immediate post-operative period, and the decision is made at a time when the patient is also processing the cancer diagnosis.

Delayed CRRM

The cancer side is treated first; the contralateral mastectomy is performed as a separate operation months or years later. This has different advantages:

• The decision is made at a calmer time, after cancer treatment is complete.
• Patients who have lived with surveillance for a year or two have a clearer sense of how much the worry of the other breast is affecting daily life.
• Adjuvant treatments (chemotherapy, radiotherapy, hormone therapy) are completed without complicating reconstruction on the unaffected side.

Disadvantages: a second recovery; a period of mismatch between the reconstructed and unaffected breast; the additional surgery does not benefit from the same operation slot as the cancer surgery.

There is no single right answer. The choice between same-operation and delayed CRRM is individual.

How much does it reduce the risk?

The figures are well established for BRCA carriers and consistent across major studies:

• Bilateral risk-reducing mastectomy reduces breast cancer risk by approximately 90–95% in BRCA1 and BRCA2 carriers (Heemskerk-Gerritsen et al., 2019). In absolute terms this means a residual lifetime risk of roughly 2–5%.
• The residual risk reflects the small amount of breast tissue that cannot safely be removed without compromising the skin envelope or the chest wall, leaving a residual lifetime risk of roughly 2–5% in BRCA carriers.
• Risk reduction does not translate one-for-one into mortality reduction, because surveillance also catches many cancers at curable stages. The all-cause mortality benefit is real but smaller than the cancer-incidence reduction. This is part of the consultation discussion.

For patients with a moderate-penetrance mutation (PALB2, CHEK2, ATM) or family-history-based high risk, the absolute risk reduction is proportionally less because the starting risk is lower, but the relative reduction (~90–95%) is similar.

The alternatives: these are real options

Risk-reducing mastectomy is one of three reasonable approaches for high-risk patients. The others are:

Enhanced surveillance

For high-risk patients, the NHS and most private pathways offer annual breast MRI surveillance, typically from age 30 for BRCA1 and BRCA2 carriers, and from age 20 for TP53 (Li-Fraumeni) carriers under NICE guidance. Annual mammography is usually added from age 40 for BRCA carriers; mammography is generally avoided under 30 in TP53 because of radiation sensitivity. The aim is to catch any cancer that does develop at the earliest, most curable stage. Surveillance does not prevent cancer; it detects it early.

Chemoprevention

Tamoxifen (typically for 5 years, in pre-menopausal patients) and NICE recommends three options for chemoprevention in the UK: tamoxifen for 5 years (typically pre-menopausal), anastrozole for 5 years (post-menopausal, first-line for high risk), or raloxifene for 5 years (post-menopausal women with a uterus, where tamoxifen/anastrozole are unsuitable). Across trials these reduce breast cancer incidence by roughly 30–50% in high-risk women. They have side-effects (hot flushes, joint aches, a small increased risk of thrombosis with tamoxifen), and the decision is individual. Chemoprevention can be combined with surveillance, and sometimes with a delayed surgical option.

Continuing as you are

For some patients, the right answer at this point in life is to continue with regular surveillance, addressing surgical risk reduction as a question to revisit later. There is no clinical pressure to act before you have weighed the options properly.

How the decision is made

The decision-making process follows a structured pathway:

1. Genetic testing and counselling: under the care of a clinical geneticist, who explains the implications of the result, the options for at-risk relatives, and the recommended surveillance schedule. Most patients seen for surgical consideration have already been through this process; for those who haven’t, referral is arranged.
2. Family history verification: where no genetic mutation has been identified, NICE CG164 requires that the family history is verified (medical records, death certificates) before bilateral risk-reducing mastectomy is offered; this is arranged through the genetics service.
3. Risk assessment: a formal estimate of lifetime breast cancer risk, taking into account the gene (where identified), family history, and personal risk factors.
4. Surgical consultation: a long appointment to discuss the operation in detail: what is removed, what is preserved, the reconstructive options, the recovery, the residual risk, and the realistic expectations for cosmetic outcome and sensation.
5. Reconstructive consultation: discussion of implant-based versus autologous (DIEP) reconstruction, immediate versus delayed, and whether nipple-sparing technique is suitable. For DIEP reconstruction, a joint consultation with a plastic-surgery colleague is arranged.
6. Time to decide: most patients take several weeks to months between consultation and surgery. There is no need to rush. Many patients have a second consultation before booking.
7. Multidisciplinary review: the operation is discussed at an MDT meeting before booking, the same standard that applies to cancer cases.

What the operation involves

• Anaesthetic: general anaesthetic.
• Length of operation: typically 4–5 hours for bilateral mastectomy with implant-based reconstruction; 8–10 hours for bilateral mastectomy with bilateral DIEP reconstruction.
• Hospital stay: 1–2 nights for implant-based reconstruction; 4–5 nights for DIEP.
• Sentinel lymph node biopsy is not performed in risk-reducing mastectomy, because there is no diagnosed cancer to drain. (If unexpected cancer is found in the mastectomy specimen, which is uncommon but does happen, sentinel biopsy may be done at a second operation if the cancer characteristics warrant it.)
• Drains: 1–2 surgical drains per side, typically removed in the first 1–2 weeks.

Nipple-sparing versus skin-sparing

For risk-reducing mastectomy, nipple-sparing technique is preferred where the anatomy allows it. Preserving both the skin envelope and the nipple-areolar complex gives the most natural-looking outcome, particularly important when there is no cancer in the breast.

Nipple-sparing is suitable when:

• The breasts are not very large or very ptotic (drooping). These can compromise blood supply to the nipple.
• The patient does not smoke, or can stop for a window around the surgery.
• The surgical team is experienced with the technique and the immediate-reconstruction pathway.

Where nipple-sparing is not suitable, skin-sparing mastectomy preserves the breast skin envelope but removes the nipple, with reconstruction filling the envelope. Nipple reconstruction can be offered later if wanted, typically as a small day-case procedure 6–12 months after the original operation.

Recovery

• First two weeks: at home with drains in place. Limited arm movement on both sides. Simple pain relief; some patients use moderate pain relief in the first week. The bilateral nature of the operation makes everyday tasks (dressing, washing) more dependent on help in the first 1–2 weeks.
• Weeks 2–6: progressive shoulder mobilisation with physiotherapy, drains usually out, return to driving around 3–4 weeks. Most patients with desk-based work return at 4–6 weeks.
• Three months: most physical activity resumed for implant-based reconstruction. DIEP needs an additional month or two for full abdominal recovery.
• One year: most patients consider themselves “back to normal”, with the reconstructed breasts having settled into their final shape.

Most patients need a revision operation at 6–12 months for symmetry, scar refinement, or, where the nipple was not preserved, nipple reconstruction. This is part of the usual arc rather than a sign of a problem.

What is preserved, and what is not

Honesty about outcomes is important, and what to expect after risk-reducing mastectomy is different from what a patient may imagine before surgery.

• Sensation in the chest wall is significantly reduced. Even when the nipple is preserved, sensation in the nipple is usually reduced and sometimes absent. Some sensation may return over months to years, but full pre-operative sensation typically does not.
• Breastfeeding is no longer possible after risk-reducing mastectomy, so timing relative to family planning is part of the discussion for younger patients.
• The reconstructed breasts are not functional breasts in the way the original tissue was; they are a reconstruction of the appearance.
• The cosmetic result is usually good, particularly with experienced bilateral surgery, but is not identical to the natural breasts. Photographs of the range of outcomes are shown at consultation.

These are not reasons to avoid the operation. For many patients, risk reduction is the priority and the trade-offs are acceptable. They are reasons to make the decision with full information.

The ovarian-cancer conversation

For BRCA1, BRCA2, and PALB2 carriers, ovarian cancer risk is also raised, and risk-reducing salpingo-oophorectomy (removal of the fallopian tubes and ovaries) is usually recommended in the late 30s for BRCA1 and the early 40s for BRCA2. This is performed by a gynaecological surgeon, not at the breast practice, but it is part of the broader risk-management plan and is coordinated with the genetics team.

The two operations are usually planned separately (most patients do not have them on the same day), and the timing is individual.

Related: Mastectomy · Reconstruction · DIEP flap reconstruction · Implant-based reconstruction · Non-cancerous breast conditions: family history section · Clinical philosophy